Pioneering innovation, fueling growth: ��ֳ�'s commitment to delivering differentiated solutions

Vandenbruaene Nathalie — Thu, 25 Apr 2024 14:43:01 +0000

Jacques Marbehant, Manufacturing Engineering & HS&E

Vandenbruaene … Thu 25/04/2024 - 16:43

At ��ֳ�, our mission has always been to create value for patients, now and into the future. We are driven by a profound sense of purpose – to push the boundaries of what's possible in order to improve the lives of people living with severe diseases. It's with great pride and excitement that we inaugurate our new state-of-the-art biotechnology plant at our ��ֳ� Braine-l'Alleud Campus. This strategic investment is not just a physical structure; it's a manifestation of our unwavering commitment to pioneering innovation and delivering unique outcomes to patients.

Over the past 18 months, our innovative spirit has yielded remarkable results: 10 + 2 positive phase 3 readouts and 14 approvals, spanning 6 patient populations across 3 continents. Our rich pipeline boasts 10 potential different medicines, each holding the promise to transform lives. We are making bold bets on highly innovative molecules, knowing that even a few "wins" can make a notable difference. As we look to the future, we are positioned for a decade and more of growth, thanks to our 5 key growth drivers and a solid foundation. By 2025, we aim to reach at least 6 billion euros in revenue, with a low 30s EBITDA margin.

Our ��ֳ� Campus at Braine-l'Alleud has been a vital part of this journey, evolving alongside the group to support our growth. What was once a high-volume location focused mainly on small-molecule chemistry has transformed over the past decade. We've invested in our first BioPilot plant, enhancing our chemistry, manufacturing, and control capabilities for biologics. Today, our high-tech campus is a thriving hub for 2,065 scientists, technicians, engineers, and manufacturing personnel from over 50 nationalities. This diverse community has grown by over 30 percent since 2018, a testament to our commitment to attracting and nurturing top talent.

To fuel our upcoming growth, we've made a strategic 300-million-euro investment in our cutting-edge biotechnology plant. Spanning 25,000 square meters, this facility is one of the largest and most modern in Belgium, creating over 150 new jobs. The plant incorporates new technologies and is designed for flexibility, superior performance, and multi-product manufacturing. With an initial capacity of 3x10,000l bioreactors and the potential to expand to 6 bioreactors, we are well-positioned to meet the growing demand for our innovative medicines.

But growth, for us, must be responsible. We have a duty to advance tomorrow's care while contributing to a more sustainable future for all. We've publicly committed to setting near- and long-term company-wide emission reduction targets in line with science-based net-zero through the Science Based Targets initiative (SBTi). Our efforts have been recognized by independent ESG rating firm Sustainalytics, who rank us as top leaders in our industry, and by the CDP, who recently upgraded our climate change rating from B to A-.

Our new Belgian Biomanufacturing Operations Center embodies our holistic approach to sustainability. It was designed with dual objectives: to surpass industry standards in environmental sustainability and to achieve superior productivity through advanced technologies. We expect significant gains in energy efficiency, water conservation, and waste reduction.

In conclusion, the inauguration of our new biotechnology plant is a proud moment for all of us at ��ֳ�. It symbolizes our relentless pursuit of innovation, our dedication to patient care, and our commitment to responsible growth. As we step into the future, we do so with confidence, knowing that we are well-equipped to deliver differentiated solutions to people living with severe diseases, today and for the decade to come.

Do you want to make your mark for patients as we prepare for our next biological product launches at ��ֳ�?

We are offering the unique opportunity to join ��ֳ� with several exciting positions directly connected to the construction of our newly launched, state-of-the-art biomanufacturing facility on our campus in Braine l’Alleud, Belgium. We are looking for collaborative, innovative people to join our Biomanufacturing team, including Production Specialists and Technicians, Quality Specialists and Compliance Specialists. If you would like to learn more and discover how you can grow a rewarding career with us, visit our Biomanufacturing careers in Belgium page .

about ucb

276 Likes

Belgium – a home for innovation

Vanco Vlastimil (��ֳ� S.A.) — Fri, 30 Sep 2022 12:36:32 +0000

Belgium – a home for innovation

Dhaval Patel, Patient Value Early Solutions

Vanco Vlastimi… Fri 30/09/2022 - 14:36

September has seen a lot of time spent discussing and shaping innovation in the EU. This week (September 28-29^th) the European Commission held its European Research and Innovation Days – their flagship event on research and innovation. This event, dedicated to promoting research and innovation across the EU, provided a space for policymakers, researchers, entrepreneurs, and the public to come together and debate and shape the future of research and innovation in Europe.

In addition, earlier this month the Commission published its 2022 European Innovation Scoreboard (EIS). The annual EIS provides a comparative assessment of the research and innovation performance of EU Member States and the relative strengths and weaknesses of their research and innovation systems. Based on their scores, Members States fall into four performance groups:

Innovation leaders (performance is above 125% of the EU average)
Strong innovators (between 100% and 125% of the EU average)
Moderate innovators (between 70% and 100% of the EU average)
Emerging innovators (below 70% of the EU average). Sweden continues to be the best performer in the EU.

Belgium was scored as an ‘innovation leader’, based on multiple factors over four main types of domains that include; framework conditions (human resources, attractiveness of research systems, digitalisation), investments, innovation activities and impact (sustainability, exports, employment). This is something I am pleased to see; it confirms that year after year Belgium remains a good place to innovate and ratifies ��ֳ�’s continued investment in our high-tech Braine Campus (one of three key strategic research centres for ��ֳ�), in the establishment of our Leuven satellite, as well as an R&D presence in our global headquarters in Anderlecht.

From ground-breaking scientific innovation to high-tech manufacturing, our Belgian ��ֳ� sites are home to a thriving and dynamic community of scientists, technicians, engineers, and manufacturing personnel who will enable us to be faster, flexible, smarter and more scalable - making our company in Belgium one of the most exciting places for creative minds and people determined to innovate, pushing the beyond the boundaries of what’s possible and shaping the future. After all we are an R&D company and R&D is all about the future.

At ��ֳ�, innovation goes into the medicines we discover, develop, and deliver. To achieve this, we work hard at providing the right surroundings and facilities, creating a culture that nurtures and fosters innovation, hiring great people and looking beyond our own boundaries to acquire new knowledge and skills. If you want to join a company that takes innovation seriously then you have arrived at the place - we have unique opportunities and exciting positions waiting for you!

Take a look

about ucb

Innovation R&D European Research and Innovation Days Braine Campus Leuven site

460 Likes

Braine Campus

Pioneering innovation, fueling growth: ��ֳ�'s commitment to delivering differentiated solutions

Leave a Comment

Belgium – a home for innovation

Leave a Comment

Braine Campus

Pioneering innovation, fueling growth: ������ֳ�'s commitment to delivering differentiated solutions

Leave a Comment

Belgium – a home for innovation

Leave a Comment

Pioneering innovation, fueling growth: ��ֳ�'s commitment to delivering differentiated solutions